Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cubbon, M. D.
Right arrow Articles by Masterton, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cubbon, M. D.
Right arrow Articles by Masterton, R. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 869-872
© 2000 The British Society for Antimicrobial Chemotherapy

Leading article

New quinolones—a fresh answer to the pneumococcus

Marc D. Cubbon and Robert G. Masterton*

Department of Clinical Microbiology, Lothian University Hospitals NHS Trust, Western General Hospital, Edinburgh EH4 2XU, UK

Streptococcus pneumoniae is the most frequent bacterial cause of community-acquired pneumonia,1 acute sinusitis2 and meningitis3 and is involved in a significant proportion of cases of acute exacerbation of chronic bronchitis.4 In addition, there is evidence that the incidence of invasive pneumococcal disease has increased.5 There is now concern over the increasing resistance of S. pneumoniae to penicillin and macrolides and the appearance of strains with reduced susceptibility to third-generation cephalosporins.6 As a result, there is a need for new agents with good activity against S. pneumoniae, especially those which can be administered orally.

As an antibiotic class, fluoroquinolones have been available for use for over two decades. However, in the last 10 years the pharmaceutical industry has poured considerable resources into producing new fluoroquinolones aimed at improving upon the shortcomings of their predecessors, particularly in terms of potency and spectrum of activity.7 Although there have been several recent and . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
R. N. Jones
Conventional dogma applied to quinolones? Time for a change
J. Antimicrob. Chemother., June 1, 2001; 47(6): 893 - 893.
[Full Text] [PDF]